Anebulo Pharmaceuticals Inc
anebulo.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2026 10-Q, filed Feb 12, 2026. Its latest SEC filing is a 15-12G from Mar 2, 2026.
10-Q for Q2 FY2026, filed Feb 12, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops selonabant, an oral and intravenous drug candidate intended to treat cannabis poisoning in children and cannabis intoxication in adults.
10-K for FY2025, filed Sep 29, 2025We are a clinical-stage pharmaceutical company developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity…View ↗
Rather than proceeding directly with the Phase 3 studies of oral selonabant in adults with ACI, we are prioritizing the advancement of a…View ↗
Our objective is to develop and commercialize new treatment options for patients suffering from cannabis-induced toxicity. Our lead product…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2025, filed Sep 29, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Feb 12, 2026
−$2MView ↗
- ▼ −19% (Loss)
- vs −$2.5M in Q2 FY2025
-
Feb 6, 2026
Approves voluntary Nasdaq delisting and SEC deregistration
The company plans to delist its shares and, after deregistration, suspend periodic SEC reports.
Sources
8-K, filed Feb 6, 2026
On February 5, 2026, the Board of Directors (the “Board”) of Anebulo Pharmaceuticals, Inc., a Delaware corporation (“Anebulo” or the…View ↗
Pediatric intravenous focus
Earlier, it described development for adult acute cannabinoid intoxication and substance addiction, centered on an oral candidate. The latest report prioritizes intravenous selonabant for children with unintentional cannabis poisoning, while retaining adult treatment as a future objective.
10-K for FY2022, filed Sep 9, 2022 10-K for FY2025, filed Sep 29, 2025We are a clinical-stage biotechnology company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”)…View ↗
Our objective is to develop and commercialize new treatments options for patients suffering from ACI and substance addiction. Our lead…View ↗
Develop future product candidates to treat substance-related addiction. We intend to leverage our expertise in the endocannabinoid system…View ↗
Who Did They Compete With?
Competes with Aelis Farma
10-K for FY2025, filed Sep 29, 2025The clinical biotechnology industry is a competitive industry characterized by technological innovation and growth. Our competitors include…View ↗
Loading...
